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Abstract
Background: Tennis elbow is a common and often extremely painful musculoskeletal condition, which has considerable
impact on individuals as well as economic implications for healthcare utilization and absence from work. Many
management strategies have been studied in clinical trials. Whilst corticosteroid injections offer short term pain relief,
this treatment is unpleasant and is used with caution due to an associated high risk of pain recurrence in the long term.
Systematic reviews conclude that there is no clear and effective treatment for symptoms of pain in the first 6 weeks of
the condition. There is a clear need for an intervention that is acceptable to patients and provides them with effective
short-term pain relief without increasing the risk of recurrence. Transcutaneous electrical nerve stimulation (TENS) is
an inexpensive, non-invasive, non-pharmacological form of analgesia that is commonly used in the treatment of pain.
TENS has very few contraindications and is simple to apply. It also benefits from being patient controlled, thereby
promoting self-management. This study aims to assess the effectiveness, in terms of pain relief, and cost-effectiveness of
a self-management package of treatment that includes TENS.
Methods/Design: The design of the study will be a two-group pragmatic randomized clinical trial. 240 participants aged
18 years and over with tennis elbow will be recruited from 20-30 GP practices in Staffordshire, UK. Participants are to
be randomized on a 1:1 basis to receive either primary care management (standard GP consultation, medication, advice
and education) or primary care management with the addition of TENS, over 6 weeks. Our primary outcome measure
is average intensity of elbow pain in the past 24 hours (0-10 point numerical rating scale) at 6 weeks. Secondary outcomes
include pain and limitation of function, global assessment of change, days of sick leave, illness perceptions, and overall
health status. A cost-effectiveness analysis will also be performed. Patient adherence and satisfaction data will be collected
at 6 weeks, 6 months and 12 months by postal questionnaire. A diary will also be completed for the first 2 weeks of
treatment. Clinical effectiveness and cost-effectiveness analyses will be carried out using an intention-to-treat approach
as the primary analysis.
Discussion: This paper presents detail on the rationale, design, methods and operational aspects of the trial.
Trial registration: Current Controlled Trials. ISRCTN87141084
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Background
Tennis elbow is a painful, disabling musculoskeletal con-
dition predominant in the 35-50 age group, and often
causes considerable pain in normal daily activities such as
gripping, carrying and lifting. Tennis elbow is tradition-
ally considered to be self-limiting, but may last for 6-18
months [1]. Its estimated prevalence in the general popu-
lation is 3-7% [2]. However, workers undertaking repeti-
tive tasks are at greater risk, representing between 35-64%
of all cases [3].
More than 40 treatments have been proposed for tennis
elbow, some of which have been investigated in clinical
trials and systematic reviews [4-6]. The overall conclusion
of these studies is that there is insufficient evidence that
any of these treatments are effective, either in the long or
short term. A recent study by Bissett et al [7] investigated
the effects of physiotherapy, corticosteroid injection, or a
'wait-and-see' approach. This investigation was similar to
two previous trials [8,9]. The results from these trials
showed dramatic short-term pain relief from corticoster-
oid injection, but poor long-term results, with higher
recurrence rate compared with the non-injection groups.
In the trial by Bisset et al [7], although physiotherapy pro-
duced slightly better results than 'wait-and-see' at six
weeks, it was not as effective for pain relief as injections.
Furthermore, from the patients' perspective, corticoster-
oid injections are seen as unpleasant and are associated
with initial worsening of pain [10]. Therefore, in the first
6-12 weeks, there is still no clear treatment for patients
who experience considerable pain and reduced function.
There is a need for an alternative intervention that pro-
vides acceptable, effective short-term pain relief without
increasing the risk of long-term recurrence.
Transcutaneous electrical nerve stimulation (TENS) is an
inexpensive, safe, non-pharmacological form of analgesia.
TENS units can be used in various clinical settings, are eco-
nomically priced, and can be readily purchased by
patients. TENS is simple to apply and is patient control-
led, promoting self-management. The neurophysiological
basis for pain relief from electrical stimulation such as
TENS derives directly from the 'gate control' theory of
pain [11]. TENS has shown positive analgesic effects in
seven systematic reviews across a range of clinical condi-
tions, e.g. chronic musculoskeletal pain [12], knee oste-
oarthritis [13] and rheumatoid arthritis [14].
Furthermore, a recent meta-analysis on postoperative use
of TENS [15] showed that a dose-dependent effect is
clearly observable, and when TENS is applied with an evi-
dence-based dose, analgesic consumption could be
reduced by up to 35%. Long-term follow up of patients
using TENS has shown a 40-58% reduction in pain [16],
coupled with a reduction in interference with work,
domestic, and social activities, increased activity levels,
and decreased use of other therapies/medication [17].
It has been argued that non-specific (placebo-related) fac-
tors of TENS comprise much of the total response. How-
ever experimental laboratory studies have clearly
demonstrated the efficacy of TENS [18,19], and clinical
trials have also shown beneficial effects compared with
sham TENS interventions [15]. Those systematic reviews
of TENS producing negative (n = 3) or inconclusive results
(n = 4) [20] included primary studies that used inade-
quate TENS dose and were underpowered [12].
Only two previous studies have investigated TENS in ten-
nis elbow. Halle et al [21] showed a decrease in mean pain
intensity after 5 days, but the brief treatment period and
small sample (n = 12 per group) restrict robust inferences.
Weng et al [22] showed a positive outcome for TENS and
a reduction in pain, but utilized non-industry standard
TENS and the sample size (n = 20 per group) was again
small.
Aims and purpose of the proposed research
The overall aim of this trial is to investigate if TENS, as a
patient-controlled adjunct to routine primary care for ten-
nis elbow, can provide superior short term pain relief and
functional improvement compared with routine primary
care alone, without increasing the risk of long-term recur-
rence.
The primary objective of the trial is to investigate, at six
weeks, pain relief from a self-management package of
treatment that includes TENS in addition to primary care
management (analgesia with advice and information
regarding tennis elbow self management), compared with
primary care management alone, in patients presenting to
their general practitioner (GP) with a first or new clinical
diagnosis of tennis elbow.
The secondary objectives of the trial are to investigate:
￿ pain relief from TENS self-management at 6 and 12
months compared with primary care management
alone.
￿ differences in secondary outcomes (participation in
work and other usual activities, use of analgesics, lim-
itation in function, and illness perceptions) between
TENS self-management and primary care manage-
ment alone, at each time point.
￿ differences in symptom recurrence between TENS
self-management and primary care management
alone, at 12 months.BMC Musculoskeletal Disorders 2009, 10:156 http://www.biomedcentral.com/1471-2474/10/156
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￿ the cost-effectiveness of TENS self-management as
an addition to primary care management.
￿ the influence of process measures, in particular
patient adherence, expectations, and satisfaction with
treatment.
Methods/Design
The design of the study will be a two-group pragmatic ran-
domized clinical trial; this is illustrated in Figure 1.
Setting and recruitment of participants
Participants will be recruited from 20-30 GP practices in
Staffordshire, England. The area covered by these practices
is primarily urban with some rural and inner city areas,
and is therefore broadly representative of the population
in the UK.
Eligibility criteria
Male and female subjects aged 18 years and above who
consult their GP with a first or new clinical diagnosis of
tennis elbow (i.e. adults with pain and tenderness in the
lateral region of the elbow, increasing on pressure on the
lateral epicondyle and on resisted dorsiflexion of the
wrist) are eligible to take part.
Participants must speak and understand English and be
willing and able to give informed written consent. Exclu-
sion criteria for the trial are: history of inflammatory
arthritis or gross structural abnormality of the elbow; con-
traindications to TENS (pacemakers, epilepsy, dermato-
logical conditions, abnormal sensation in the affected
arm, indwelling electrical pumps/pacemakers, and preg-
nancy); neuropathic pain; inability to apply TENS inde-
pendently, complete written questionnaires, or read
instruction leaflets written in English.
Recruitment
GPs who are networked on the EMIS data system (a com-
puterized system that maintains electronic patient
records) will enter an appropriate diagnostic code (Read
Code) for tennis elbow, and a 'pop-up' computer prompt
will remind the GP that the patient is eligible for inclusion
in the trial. At this point the GP will have the facility to
enter a 'flag' onto the computer system if patients are
unsuitable for the trial. A similar system to recruit patients
to previous musculoskeletal trials in primary care has
been used in this Centre [23]. GPs who are not networked
on the EMIS system will be provided with a manual
prompt card regarding eligibility for the trial and exclu-
sion criteria. Suitable patients will be told about the trial
and the Tennis Elbow Clinic. Interested patients will be
given an information leaflet about the trial and the GP
will then obtain written consent to contact by a study
nurse, which will be faxed to the research centre along
with the patient's details.
All patients who consent to further contact by a study
nurse will then receive treatment by the GP, including
analgesic prescription (where appropriate) and/or advice
(e.g. paracetamol or co-codamol up to 8 tablets per day).
Patients receiving prescribed anti-inflammatory or pain-
relieving medication will be permitted to continue a sta-
ble dose. GPs will be asked to avoid corticosteroid injec-
tions or referral to physiotherapy for the first 6 weeks of
the patient's participation in the trial.
The study nurse will telephone patients within two work-
ing days to provide further information about the trial,
establish that the patient has not received steroid injection
or referral to physiotherapy from the GP and is eligible for
the trial, and make an appointment for the Tennis Elbow
Clinic. Patients will be notified that the consultation may
take up to an hour. They will then be sent a letter to con-
firm their appointment, information about the clinic, and
a duplicate trial information leaflet. If the appointment is
within 24 hours, oral instructions about the clinic will be
given by the study nurse.
At the Tennis Elbow Clinic the study nurse will welcome
patients and check their details. The study nurse will then
explain the purpose of the clinic and the research being
hosted within the clinic, check eligibility, and ask patients
whether they wish to take part in the trial. Patients who
are not eligible or do not wish to take part in the trial will
be seen by a second treatment clinician (physiotherapist
or nurse) and given information and advice on managing
their tennis elbow according to usual practice. For patients
giving preliminary consent, the study nurse will explain
the trial in detail, gain written informed consent including
permission for medical record review. The patient will
then be provided with a baseline questionnaire to com-
plete. The study nurse will check the baseline question-
naire for completeness, prior to randomization. The study
nurse will remain blinded to treatment allocation
throughout the trial. A post-study audit of the success of
blinding procedures will be completed and a procedure
for reporting incidents where blinding has been compro-
mised will be in place.
Baseline questionnaire
In addition to baseline outcome measurements, as appro-
priate, the baseline questionnaire will include:
￿ Sociodemographic variables
￿ Work-related variables: hours of paid work, job type,
physical work load (items from questionnaire devel-BMC Musculoskeletal Disorders 2009, 10:156 http://www.biomedcentral.com/1471-2474/10/156
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Trial flow chart Figure 1
Trial flow chart.
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oped by Bot et al [24]), psychosocial work environ-
ment (items from Job Content Questionnaire [25]).
￿ Clinical characteristics: history of elbow pain, previ-
ous treatments, intensity and duration of symptoms,
other co-existing pain problems.
￿ Beliefs and expectations regarding treatment: items
of the revised Illness Perceptions Questionnaire (IPQ-
R) [26] supplemented with specific questions on treat-
ment expectations
￿ Illness perceptions (including personal control and
expectations regarding duration, items from IPQ-
R)[26].
Randomization and Treatment Allocation
After completing baseline assessment consenting patients
will be randomly allocated in a 1:1 ratio to six weeks of
either primary care management alone or primary care
management with TENS. Prior to the start of the trial, the
trial coordinator, who is not involved in the selection and
inclusion of patients, will supervise preparation of num-
bered, opaque and sealed tamper-proof envelopes con-
taining the treatment allocation. The random sequence
(based on simple randomization) will be generated using
a computerized random-number generator. At the
research clinic, after final enrolment and baseline assess-
ment, the participant is allocated an individual study
number, and receives the appropriate envelope from the
research nurse. The participant then meets with the treat-
ing clinician, and the envelope is opened. The use of sep-
arate study and treating clinicians and sealed envelope
randomization will ensure independent selection of
patients and concealed allocation of treatment.
Following randomization, the treating clinician will
deliver whichever intervention the patient has been rand-
omized to receive. The clinician will also give each patient
a two-week daily diary to measure pain intensity and
record usage of TENS and analgesics. Patients from both
treatment arms will be advised that they can access their
GP for ongoing care in the usual way if their elbow pain
becomes worse.
Patients will be sent postal questionnaires at 6 weeks, 6
months and 12 months, with reminder letters 2 and 4
weeks following first mail-out for those who do not
respond. The study nurse will telephone patients who do
not respond to the first reminder letter at six week follow
up or the second reminder letter at six- or twelve-month
follow up, to collect minimum data on the primary out-
come.
Interventions
Primary care management alone (control intervention)
At the research clinic the treatment clinician will provide
patients with the tennis elbow information leaflet and
will reinforce the messages on advice and education con-
tained within it. Patients will be informed of the usually
self-limiting nature of tennis elbow and advised that
while the elbow pain persists, they should avoid, when-
ever possible, repetitive elbow extension, forceful elbow
activities, or activities that provoke pain. Potential ergo-
nomic impact factors derived from sporting or working
activities will be discussed and self-management in the
form of rest/avoidance suggested, although absolute rest
of the arm will not be advocated. In addition, the patient
will be advised to gradually increase activity once acute
pain has settled down and some basic progressive exer-
cises will be explained.
Primary care management plus patient-controlled TENS
In addition to the control intervention described above,
patients randomized to this group will be given a TENS
machine and instructed on how to use it. They will be
shown how to apply TENS locally, to the lateral aspect of
the elbow and forearm, and will be encouraged to use the
TENS machine at least once per day for one 45-minute
treatment session, for each day that symptoms persist.
Patients may use the TENS machine more often if they
wish. The TENS parameter settings will be high frequency
(110 Hz) at a pulse duration of 200 μs (frequency and
pulse duration will be pre- programmed), with a self-
selected intensity described as of 'strong but tolerable sen-
sation' (measured as amplitude mA). Patients will be
informed that they should feel an uncomfortable (but not
painful) 'tingling' sensation and that they may experience
muscle contractions and a local cooling of the area.
Patients will be encouraged to use the TENS machine for
a minimum of six weeks unless their symptoms have fully
resolved before then.
The selected TENS settings are those that, on the basis of
the literature and our pilot laboratory work, are most
likely to achieve analgesia. Patients will be required to rest
during, and for approximately one hour after, the stimu-
lation period, which will last 45 minutes. Application just
before usual bedtime will be recommended so that the
rest period can be incorporated into normal rest/sleep
periods. An exact timing of stimulation is not essential
provided that participants adhere to these conditions. The
application of TENS will be the responsibility of the
patient but the treating clinician will make an appoint-
ment for a telephone consultation approximately two
days after the clinic to review the technical application of
TENS and will be available via telephone (during the six-BMC Musculoskeletal Disorders 2009, 10:156 http://www.biomedcentral.com/1471-2474/10/156
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week treatment period) to assist patients with technical
queries.
Training of the treatment clinicians
Prior to recruitment of participants into the trial, the study
treating clinicians will be trained to deliver the interven-
tions in a standardized way. Training will include infor-
mation regarding the clinical syndrome of tennis elbow,
presenting symptoms, and treatment options. Guidance
in the delivery of specific advice, in respect of work and
ergonomic factors and exercises outlined in the leaflet,
will also be given. Specific training in TENS will include:
how it works, how it should be applied, how to check for
contraindications and precautions, and how to train
patients in its use. Technical difficulties with the TENS
units are unlikely to occur but training will also be pro-
vided in fault finding in order to support patients in their
use of TENS at their follow-up phone call. The core train-
ing will be covered in one day with a further day's training
two weeks later, just prior to the start of the clinics, to
practise delivering the interventions. A written manual of
instructions on how to deliver the interventions will be
given to each clinician.
Audit of interventions
At the clinic, the study clinician will complete a case
report form for each patient participating in the trial; this
will record assessment findings relating to elbow pain and
document advice and treatment given in clinic. Ten per-
cent of these forms will be audited, and members of the
study team will also visit the clinic periodically to ensure
the appropriate delivery of advice and treatment.
Equipment
The TENS units to be used (TensCare itouch Easy™) will be
pre-set with the stimulation parameters. Patients will be
given basic coaching in use of the equipment - e.g. switch-
ing on and off and changing the battery. However,
patients will not be instructed on how to change pro-
grammes within the machine and will be asked to ensure
they do not attempt to do this.
Outcome Measures
Clinical outcomes will be measured at baseline in clinic
and by postal questionnaire at six weeks, six months and
12 months. There will also be a daily diary issued at clinic
to be completed by participants over the first two weeks of
treatment and returned by post on completion. The diary
for the participants receiving TENS will have additional
questions to record daily use of the TENS machine. Spe-
cific content is as follows:
￿ Intensity of elbow pain in the past 24 hours (0-10
point Numerical Rating Scale, NRS);
￿ Sick leave or inability to carry out usual activities due
to elbow pain;
￿ Number and type of analgesics taken per day;
￿ The use of TENS in minutes per day (for the TENS
group).
Questionnaires at 6 weeks, 6 months and 12 months after 
randomization
All participants will receive a postal questionnaire con-
taining primary and secondary outcome measures. As the
main focus of the trial is reduction of pain in patients with
tennis elbow the primary outcome will be the average
intensity of elbow pain over the past 24 hours scored on a
0-10 NRS scale. Secondary outcomes will be:
￿ Days sick leave and ability to carry out usual activi-
ties
￿ Self reported global change in elbow pain (5-point
adjectival scale: much better - much worse [9])
￿ Pain and limitation in function (Patient-rated Tennis
Elbow Evaluation (PTEE) [27])
￿ Illness perception (items in the IPQ-R [26])
￿ General Health: the EuroQoL EQ-5D [28] and SF-12
SF-6D [29].
￿ Health care resource use (including visits to health
care professionals, and use of co-interventions and
analgesics)
￿ Process measures:
 Changes in beliefs and expectations of treatment
(IPQ-R and specific items)
 Satisfaction with treatment, feasibility, and appli-
cability of TENS (0-10 NRS)
 Compliance with treatment (adherence to
advice/exercise, and use of TENS in minutes per
day in the TENS group).
Sample size
In two previous trials of tennis elbow in primary care in
the UK and the Netherlands, there was a 25% reduction in
pain (1.5-point mean change (standard deviation 2.6) on
a 0-10 NRS) in the usual care group at 4-6 weeks follow-
up [8,9]. The overall mean baseline pain score was 6-
points in both trials (after standardizing to a 0-10 pointBMC Musculoskeletal Disorders 2009, 10:156 http://www.biomedcentral.com/1471-2474/10/156
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scale). According to Farrar et al [30], a 20% reduction in
pain (on a numerical rating scale) is clinically relevant. In
order to detect a 20% difference compared to usual care
(1.2 points, assuming a 2.7-point (45%) reduction in
pain score in the TENS self-management group and a 1.5-
point (25%) reduction in the usual care group, with
pooled SD of 2.6), we would need complete data for 198
patients (99 in each study group), for 90% power at a 5%
two-tailed significance level. To take account of a maxi-
mum 15% loss of data (this level of follow-up has been
achieved in previous similar studies in our Centre), we
would need 117 participants per treatment group. We will
therefore aim to recruit 120 patients per group; 240
patients altogether.
An independent trial steering group will monitor adher-
ence to interventions and recruitment rates and general
progress against the plan.
Analysis
Descriptive statistics of baseline characteristics will be
compared between study groups. An unadjusted analysis
will focus on analysing the primary outcome measure
(average pain intensity) at 6 weeks (the primary end-
point), using the t test for independent samples. Mean
estimates and 95% confidence intervals will be presented
for differences between groups. The robustness of the
findings will be tested through sensitivity analyses (see
below). In addition, multilevel analysis will be carried out
to estimate the overall effect of TENS treatment over time,
taking account of clustering due to repeated measure-
ments on the same individuals. Treatment main effects
and the interaction of treatment and time will be mod-
elled for short to long-term outcome data (6 weeks, 6
months and 12 months) and separately for the 2-week
post-treatment time period covered by the pain diaries.
Differences in secondary outcome measures will be esti-
mated using similar statistical methods. In all cases, a sig-
nificance level of 5% (two-tailed) is pre-stipulated.
Hypothesis testing will be performed blind to treatment
group.
Sensitivity analysis
The primary analysis will be carried out using an intention
to treat (ITT) approach; a sensitivity analysis will use a per
protocol approach [31], excluding patients who did not
adhere to intervention protocols, received additional
treatments during the first 6 weeks (e.g. injection or phys-
iotherapy), or dropped out of the study. Analysis will be
carried out in two ways: (a) through a complete-case anal-
ysis, i.e. only participants with complete outcome data
will be analysed; (b) through an imputed-case analysis,
i.e. the multiple imputation method will be used to
impute values for missing data (assumed to be missing at
random) [32].
A second sensitivity analysis will adjust for the following
baseline covariates: age, gender, pain intensity (primary
outcome measure) and corresponding baseline value for
secondary outcome measures, if applicable; e.g. baseline
function scores for the analysis involving limitation in
function during follow-up.
Process evaluation
Descriptive statistics will be used to describe beliefs and
expectations regarding treatment, compliance to advice
regarding use of analgesics and use of the TENS units, and
satisfaction with treatment. Compliance with TENS will
be ascertained from questions about the duration, fre-
quency, and dosage of use as recorded by the patient (in
the two-week diary and follow-up questionnaire at 6
weeks). In exploratory subgroup analyses we will analyse
whether better outcomes in key outcome measures are
associated with:
￿ older/younger patients
￿ female/male sex
￿ manual/non-manual workers
￿ higher baseline expectations of or beliefs in TENS
￿ higher scores on satisfaction
￿ better compliance with advice or use of TENS.
Economic evaluation
The economic analysis will adopt a societal perspective,
where all relevant costs are measured, including direct
health care costs incurred within both public and private
sectors, and the indirect costs outside the health care sec-
tor associated with productivity loss. A cost-effectiveness
analysis will be carried out with change in pain intensity
as the clinical outcome of interest. Additionally, a cost-
utility analysis will be performed to enable comparisons
to be drawn with other areas of health care; utility will be
measured using QALY values, which will be derived sepa-
rately from (i) the EuroQoL EQ5D, and (ii) the SF-12 SF-
6D. The ceiling QALY will be 1, which is equivalent to the
year's follow up spent in full health.
Data on health care resource use and time off work will be
obtained from the patient questionnaires; a medical
record review will be used to verify the self-complete data.
NHS care will be costed as national averages [33], with
inpatient and outpatient episodes costed using NHS refer-
ence costs. Owing to the paucity of high-quality unit cost
data for private health care consultations, these data will
be costed as the NHS equivalent. The British National For-
mulary will be used to cost prescribed medication. CostsBMC Musculoskeletal Disorders 2009, 10:156 http://www.biomedcentral.com/1471-2474/10/156
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of absenteeism from paid work will be estimated by mul-
tiplying the reported number of days off work during the
12-month follow up period by the average daily wage, and
stratifying by hourly mean income according to sex, full/
part-time work status, and standard occupational classifi-
cation (SOC 2000) [34,35].
Cost data alongside trials are invariably skewed. We will
calculate 95% confidence intervals around differences in
mean costs, EQ-5D scores, QALYs, and pain change scores
using conventional parametric methods and bias-cor-
rected and accelerated (BCa) bootstrapping (1000 replica-
tions) [36]. The aim of the economic evaluation will be to
estimate and compare the additional costs of TENS com-
pared to usual primary care only and relate this to the
additional effects of TENS. An incremental approach will
be used in the analysis if neither treatment group is dom-
inant, with differences in costs and health outcomes
expressed using an incremental cost per 1-point improve-
ment in pain intensity (i.e. the incremental cost-effective-
ness ratio [ICER]). Similarly, for the cost-utility analysis
we will analyse the incremental cost per QALY (i.e. via the
incremental cost-utility ratio [ICUR]). Estimates of ICER
and ICUR will be derived and bootstrap samples will be
generated to compose cost utility planes (which show
graphically the variability in the data) [37]. Cost effective-
ness acceptability curves (CEACs) will be plotted to quan-
tify, from the bootstrap data, the probabilities of the
interventions being cost effective across a range of ceiling
ICER values (otherwise referred to as the willingness-to-
pay threshold values) [38].
An independent data monitoring committee will monitor
the trial every 6 months. There will be no interim analyses.
Ethical Approval
Ethical approval was obtained from the South Stafford-
shire Local Research Ethics Committee in May 2009 (ref
number 09/H1203/31).
Discussion
The TATE trial will investigate the clinical and cost effec-
tiveness of TENS in addition to usual primary care man-
agement for patients with tennis elbow. TENS may prove
to be a suitable intervention for tennis elbow as it may
help to reduce pain in the early stages of the condition,
without the risk of side effects and/or recurrence in the
long-term, and is an attractive treatment option as it facil-
itates self-management of the condition.
We estimate that we will recruit 240 patients to the trial in
15 months if we involve 20-30 GP practices from north
Staffordshire PCT. Trial recruitment is scheduled to begin
in August 2009. Follow up is targeted for completion by
November 2011 and results should be finalized for publi-
cation in spring 2012.
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